Internship
Confirmed live in the last 24 hours
Develops software as prescription medical treatments
$22Hourly
New York, NY, USA
This is a hybrid internship requiring in-office attendance on Wednesdays and Fridays.
You match the following Click Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. Their collaboration with Boehringer Ingelheim highlights their commitment to advancing digital therapeutics, particularly in treating conditions like schizophrenia. The goal of Click Therapeutics is to provide effective digital solutions for patients with unmet medical needs, continuously improving their applications using real-world evidence.
Company Size
51-200
Company Stage
Debt Financing
Total Funding
$93.9M
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Unlimited Paid Time Off
Flexible Work Arrangement
Stock Options
Performance Bonus
Fertility Treatment Support
Professional Development Budget
Commuter Benefits
Click Therapeutics launches Software-Enhanced Drug therapies.
NEW YORK-(BUSINESS WIRE)-David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner.
PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn(TM).
What You Should Know:– Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.– Click’s expansion into cardiometabolic disease follows successful DTx development efforts in other areas, including migraine prevention, depression, schizophrenia, and opioid use disorder.Strengthening the DTx PipelineThe acquisition includes several key assets from Better Therapeutics:AspyreRx (BT-001): The first FDA-authorized DTx for type 2 diabetes.The first FDA-authorized DTx for type 2 diabetes. BT-004: A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH).A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH). BT-002: A DTx designed to reduce blood pressure in patients with hypertension.A DTx designed to reduce blood pressure in patients with hypertension. BT-003: A DTx focused on lowering LDL cholesterol in patients with hyperlipidemia.The strategic acquisition significantly expands Click’s DTx portfolio, complementing their existing offerings in psychiatry, CNS, and pain management. It also strengthens their position in the rapidly growing market for obesity and cardiometabolic disease treatments.A Personalized Approach to Weight ManagementClick’s existing DTx solutions focus on psychiatry, CNS, and pain disorders. By integrating Better Therapeutics’ assets, Click gains immediate traction in the rapidly growing cardiometabolic space, complementing their current offerings.Click emphasizes the importance of personalized treatment plans for obesity, a complex chronic disease
- Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.